Comparison
Creatine Monohydrate vs PT-141
Side-by-side of Creatine Monohydrate and PT-141. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Creatine Monohydrate
Creatine monohydrate supplement guide: 3-5 g/day raises phosphocreatine stores, lifts anaerobic output 5-15%, supports lean mass and cognition under sleep loss.
PT-141
PT-141 peptide (bremelanotide, Vyleesi): MC4R agonist for libido and erectile dysfunction. 1.75 mg subcutaneous, 30 to 60 min onset, 2 to 4 h half-life.
Effects at a glance
Creatine Monohydrate
- •Increases anaerobic strength and power output by ~5 to 15% across multiple training studies
- •Adds ~1 to 2 kg of lean body mass over 4 to 12 weeks, partly intracellular water and partly true tissue gain
- •Improves 1-rep max on bench and squat by ~5 to 10% versus placebo in resistance-trained adults
- •Cognitive benefit appears mainly under sleep deprivation or high mental load, less so in well-rested individuals
- •Saturation reached in ~28 days at 3 to 5 g/day, or ~5 to 7 days with a 20 g/day loading phase
- •No evidence of renal harm in healthy adults across long-term studies; caution in pre-existing severe renal disease
PT-141
- •Cyclic 7-amino-acid synthetic peptide and melanocortin receptor agonist (MC4R-preferring)
- •FDA approved in 2019 as Vyleesi for hypoactive sexual desire disorder in pre-menopausal women
- •Acts centrally on hypothalamic sexual-desire circuits rather than peripherally on vasculature
- •On-demand dosing: subcutaneous 1.75 mg approximately 45 minutes before sexual activity
- •Common adverse effects: nausea (~40%), flushing, headache, injection-site reactions, hyperpigmentation
- •Off-label male ED use is documented but not FDA approved; mechanism is distinct from PDE5 inhibitors
Side-by-side
| Attribute | Creatine Monohydrate | PT-141 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | creatine | Bremelanotide, Vyleesi |
| Half-life (hr) ↗ | 3 | 2.7 |
| Typical dose (mg) ↗ | 5000 | 1.75 |
| Dosing frequency | daily | as needed (max once per 24 hours, max 8 per month) |
| Routes | oral | subcutaneous |
| Onset (hr) | 168 | 0.75 |
| Peak (hr) | - | 1.5 |
| Molecular weight | 149.15 | 1025.18 |
| Molecular formula | C4H9N3O2 | C50H68N14O10 |
| Mechanism | Donates a phosphate group to ADP via creatine kinase, regenerating ATP during high-intensity, short-duration efforts. | Synthetic agonist of melanocortin receptors with preference for MC4R, expressed in hypothalamic and limbic circuits regulating sexual motivation. Engages central pathways distinct from peripheral PDE5-mediated vasodilation. |
| Legal status | Dietary supplement (most jurisdictions) | Prescription only as Vyleesi; FDA-approved 2019 for HSDD in pre-menopausal women. Compounded versions sold off-label for male sexual function are research-use-only grey market. |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance) for the FDA-approved Vyleesi formulation |
| Pregnancy | Insufficient data | Not recommended; contraindicated during pregnancy per Vyleesi label |
| CAS | 57-00-1 | 189691-06-3 |
| PubChem CID | 586 | 9941379 |
| Wikidata | Q408389 | Q422059 |
Safety profile
Creatine Monohydrate
Common side effects
- water retention
- mild GI upset at loading doses
- weight gain (2 to 4 lb from intracellular water)
Contraindications
- severe renal impairment
Interactions
- caffeine (high-dose acute): mixed data on ergogenic interference; chronic use appears compatible(minor)
- nephrotoxic drugs (NSAIDs, cyclosporine): theoretical additive renal strain in at-risk patients(moderate)
PT-141
Common side effects
- nausea (~40%)
- flushing
- headache
- injection-site reactions
- hyperpigmentation (focal, gums, face, breasts)
- transient blood pressure increase (~6 mmHg systolic)
Contraindications
- uncontrolled hypertension
- established cardiovascular disease
- pregnancy
- naltrexone co-administration (reduces opioid efficacy due to MC receptor crosstalk)
Interactions
- naltrexone (oral): bremelanotide reduces oral naltrexone exposure significantly; avoid co-administration(major)
- antihypertensives: transient BP rise after bremelanotide can offset BP control(moderate)
- PDE5 inhibitors (sildenafil, tadalafil): no documented adverse interaction; mechanisms are non-overlapping(minor)
Which Should You Take?
Creatine Monohydrate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. PT-141 is the right call when one of the conditionals below applies.
- → If your priority is strength or hypertrophy, pick Creatine Monohydrate.
- → If your priority is focus or working memory, pick Creatine Monohydrate.
- → If your priority is sexual function, pick PT-141.
- → If your priority is libido, pick PT-141.
Edge case: If you want to avoid research-only / gray-market sourcing, Creatine Monohydrate is the more accessible choice.
Default choice: Creatine Monohydrate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for PT-141 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Creatine Monohydrate and PT-141?
Creatine Monohydrate and PT-141 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Creatine Monohydrate or PT-141?
Creatine Monohydrate half-life is 3 hours; PT-141 half-life is 2.7 hours.
Can you stack Creatine Monohydrate with PT-141?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper